Treatment schema. Auto-SCT: patients who underwent auto-SCT with BEAM conditioning per institutional guidelines. Conditioning regimens other than BEAM were allowed, per treating physician’s discretion. Consolidation: blinatumomab started 6 weeks (±1 week) after auto-SCT. Patients with CR or PR based on pretransplant PET/CT received blinatumomab as a continuous IV infusion (CIVI) at 9 μg/d for 1 week and then 28 μg/d for 3 weeks (total of 4 weeks).